Organ-on-a-Chip Microphysiological Systems for Human-Relevant Drug Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for alternatives to animal studies for developing novel pharmaceuticals and countermeasures against biothreats, as current methods are inefficient and unethical, particularly for national defense applications.
Innovation Solution
The development of integrated microphysiological systems, specifically 'Organ-on-a-Chip' systems, which are microfluidic devices containing living human cells that mimic three-dimensional tissue-tissue interfaces and complex organ functions, allowing for the analysis of drug efficacy, toxicity, pharmacokinetics, and pharmacodynamics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If animal studies are used for pharmaceutical development, then safety testing can be performed, but ethical concerns arise and the results may not accurately predict human responses
Solution Approach 1:
The patent creates microphysiological systems that are simplified copies of human organs and tissues, using human cells cultured in microfluidic devices to replicate organ-level functions. These systems provide human-relevant data without requiring animal subjects, directly resolving the contradiction between obtaining reliable human response data and avoiding ethical concerns about animal testing
Solution Approach 2:
The patent introduces microphysiological systems as an intermediary between traditional animal testing and direct human testing. These systems serve as a middle ground that provides human-relevant physiological data while avoiding the ethical issues of animal testing and the risks of direct human experimentation
2Reliability
If traditional drug development methods are used, then comprehensive safety and efficacy testing can be performed, but the development timeline is extended and costs increase
Solution Approach 1:
The patent segments the complex process of organ-level testing into modular microphysiological systems that can be developed, validated, and implemented independently. Each microphysiological system targets specific organ functions or disease mechanisms, allowing parallel development and testing approaches that accelerate the overall drug development timeline while maintaining comprehensive safety and efficacy assessment
Solution Approach 2:
The patent enables preliminary safety and efficacy testing to be performed using microphysiological systems before proceeding to more extensive animal or clinical studies. This preliminary action filters out ineffective or toxic compounds early in the development process, reducing the time and resources required for subsequent testing phases
Data Source
AI summary
The invention provides integrated Organ-on-Chip microphysiological systems representations of living Organs and support structures for such microphysiological systems.